Alimera Sciences, Inc. (NASDAQ:ALIM)

CAPS Rating: 1 out of 5

ALIM News and Commentary

Caps

How do you think ALIM will perform against the market?

Add Stock to CAPS Watchlist

All Players

68 Outperform
16 Underperform
 

All-Star Players

5 Outperform
7 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top ALIM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.83)
Submitted January 11, 2016

When these inevitable broad declines come along, I start looking for two kinds of stocks: companies with potential that have been overly punished, and companies which are doomed long-term and haven't been punished enough. I try and green thumb the… More

rknapton (20.74)
Submitted July 24, 2013

Short. Biopharma. $0 Revenues. Consistent share dilution.

ALIM VS S&P 500 (SPY)

ALIM Summary

Recent Community Commentary

Read the most recent pitches from players about ALIM.

Recs

0
Member Avatar DeathStock (97.67) Submitted: 4/24/2016 6:32:43 PM : Outperform Start Price: $2.33 ALIM Score: -63.49

http://caps.fool.com/Blogs/alimera-sciences-is-it-time/1074521

Recs

2
Member Avatar zzlangerhans (99.83) Submitted: 1/11/2016 8:49:40 AM : Outperform Start Price: $2.51 ALIM Score: -74.89

When these inevitable broad declines come along, I start looking for two kinds of stocks: companies with potential that have been overly punished, and companies which are doomed long-term and haven't been punished enough. I try and green thumb the former and red thumb the latter. I've been an Alimera bear for quite some time, but the stock has now been beaten down enough that I'll hazard an outperform rating ahead of a predicted ramp in Iluvien sales in 2016 once a J code has been granted. I wouldn't use real money to bet that Alimera can achieve positive cash flow from Iluvien based on their optimistic projections, but I'll risk an accuracy point to follow the story in the virtual realm.

Recs

1
Member Avatar rknapton (20.74) Submitted: 7/23/2013 8:12:18 PM : Underperform Start Price: $5.10 ALIM Score: +124.37

Short. Biopharma. $0 Revenues. Consistent share dilution.

Leaderboard

Find the members with the highest scoring picks in ALIM.

Score Leader

htsigns

htsigns (< 20) Score: +230.69

The Score Leader is the player with the highest score across all their picks in ALIM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Halffrenzy 25.08 7/5/2013 Underperform 5Y $4.95 -72.12% +58.25% +130.37 0 Comment
rknapton 20.74 7/24/2013 Underperform 5Y $5.10 -72.94% +51.43% +124.37 1 Comment
ultrasounddoc < 20 5/9/2014 Underperform 5Y $5.42 -74.54% +36.99% +111.53 0 Comment
KidJones 30.32 2/14/2013 Underperform 5Y $2.36 -41.53% +69.50% +111.02 0 Comment
pro64grammer 28.77 12/19/2013 Underperform 5Y $4.46 -69.06% +41.85% +110.91 0 Comment
mikefee 91.90 6/26/2014 Underperform 5Y $6.01 -77.04% +31.44% +108.48 0 Comment
Imhilion 20.99 12/2/2013 Underperform 1Y $2.36 -41.49% +42.05% +83.54 0 Comment
IdahoInvestor 29.65 1/18/2012 Underperform 5Y $1.20 +15.00% +97.56% +82.56 0 Comment
SimonSaysSell 98.55 10/31/2013 Underperform NS $2.14 -35.51% +45.96% +81.47 0 Comment
barcharttracker1 < 20 3/4/2016 Underperform NS $1.82 -24.18% +28.55% +52.72 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.96 3/28/2014 Underperform 3W $7.20 -80.83% +38.61% +119.44 0 Comment
TrackBWS 97.48 11/11/2011 Underperform NS $1.84 -33.70% -5.20% +28.49 11/28/2011 @ $1.22 0 Comment
TrackOppenheimer 66.44 12/27/2010 Outperform NS $9.00 -84.67% +105.47% -190.14 0 Comment
TrackRodmanRen < 20 10/11/2010 Outperform NS $10.99 -84.26% +7.27% -91.52 11/14/2011 @ $1.73 0 Comment

Featured Broker Partners